Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA

Choong Eun Jin; Bonhan Koo; Tae Yoon Lee; Kyudong Han; Seok Byung Lim; In Ja Park; Yong Shin

doi:10.1002/advs.201800614

Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA

Choong Eun Jin, Bonhan Koo, Tae Yoon Lee, Kyudong Han, Seok Byung Lim, In Ja Park, Yong Shin

Division of Life Sciences

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Cell-free nucleic acids (cfNAs) are emerging diagnostic biomarkers for monitoring the treatment and recurrence of cancers. In particular, the biological role and clinical usefulness of cfNAs obtained from the plasma of patients with various cancers are popular and still intensely explored, yet most studies are limited by technical problems during cfNA isolation. A dimethyl dithiobispropionimidate (DTBP)-based microchannel platform that enables spontaneous cfNA capture in 15 min with minimal cellular background and no requirements for use of bulky instruments is reported first. This platform identified KRAS and BRAF hot-spot mutations following cfDNA isolation from the blood plasma and tissues obtained from 30 colorectal cancer patients. The correlation of mutations between the primary tissues and plasma from the patients was high using this platform with whole genome sequencing compared to the spin-column method. This platform can also be combined with various detection approaches (biooptical sensor, Sanger sequencing, and polymerase chain reaction (PCR)) for rapid, simple, low-cost, and sensitive circulating tumor DNA detection in blood plasma. The efficiency and versatility of this platform in isolating cfNAs from liquid biopsies has applications in cancer treatment and precision medicine.

Original language	English
Article number	1800614
Journal	Advanced Science
Volume	5
Issue number	10
DOIs	https://doi.org/10.1002/advs.201800614
Publication status	Published - 2018 Oct

Bibliographical note

Funding Information:
This study was supported by the Ministry of Science, ICT, and Future Planning (MSIP) through the National Research Foundation of Korea (NRF) (2017R1A2B4005288), and also supported by a grant from the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI16C-0272-010016), and was also supported by a grant (2017-7031, 7034) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.

Publisher Copyright:
© 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All Science Journal Classification (ASJC) codes

Medicine (miscellaneous)
Chemical Engineering(all)
Biochemistry, Genetics and Molecular Biology (miscellaneous)
Materials Science(all)
Engineering(all)
Physics and Astronomy(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/advs.201800614

Cite this

@article{b4e571d3a0444e948daefc68fbdc802d,

title = "Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA",

abstract = "Cell-free nucleic acids (cfNAs) are emerging diagnostic biomarkers for monitoring the treatment and recurrence of cancers. In particular, the biological role and clinical usefulness of cfNAs obtained from the plasma of patients with various cancers are popular and still intensely explored, yet most studies are limited by technical problems during cfNA isolation. A dimethyl dithiobispropionimidate (DTBP)-based microchannel platform that enables spontaneous cfNA capture in 15 min with minimal cellular background and no requirements for use of bulky instruments is reported first. This platform identified KRAS and BRAF hot-spot mutations following cfDNA isolation from the blood plasma and tissues obtained from 30 colorectal cancer patients. The correlation of mutations between the primary tissues and plasma from the patients was high using this platform with whole genome sequencing compared to the spin-column method. This platform can also be combined with various detection approaches (biooptical sensor, Sanger sequencing, and polymerase chain reaction (PCR)) for rapid, simple, low-cost, and sensitive circulating tumor DNA detection in blood plasma. The efficiency and versatility of this platform in isolating cfNAs from liquid biopsies has applications in cancer treatment and precision medicine.",

author = "Jin, {Choong Eun} and Bonhan Koo and Lee, {Tae Yoon} and Kyudong Han and Lim, {Seok Byung} and Park, {In Ja} and Yong Shin",

note = "Funding Information: This study was supported by the Ministry of Science, ICT, and Future Planning (MSIP) through the National Research Foundation of Korea (NRF) (2017R1A2B4005288), and also supported by a grant from the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI16C-0272-010016), and was also supported by a grant (2017-7031, 7034) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea. Publisher Copyright: {\textcopyright} 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim",

year = "2018",

month = oct,

doi = "10.1002/advs.201800614",

language = "English",

volume = "5",

journal = "Advanced Science",

issn = "2198-3844",

publisher = "Wiley-VCH Verlag",

number = "10",

}

TY - JOUR

T1 - Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA

AU - Jin, Choong Eun

AU - Koo, Bonhan

AU - Lee, Tae Yoon

AU - Han, Kyudong

AU - Lim, Seok Byung

AU - Park, In Ja

AU - Shin, Yong

N1 - Funding Information: This study was supported by the Ministry of Science, ICT, and Future Planning (MSIP) through the National Research Foundation of Korea (NRF) (2017R1A2B4005288), and also supported by a grant from the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI16C-0272-010016), and was also supported by a grant (2017-7031, 7034) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea. Publisher Copyright: © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

PY - 2018/10

Y1 - 2018/10

N2 - Cell-free nucleic acids (cfNAs) are emerging diagnostic biomarkers for monitoring the treatment and recurrence of cancers. In particular, the biological role and clinical usefulness of cfNAs obtained from the plasma of patients with various cancers are popular and still intensely explored, yet most studies are limited by technical problems during cfNA isolation. A dimethyl dithiobispropionimidate (DTBP)-based microchannel platform that enables spontaneous cfNA capture in 15 min with minimal cellular background and no requirements for use of bulky instruments is reported first. This platform identified KRAS and BRAF hot-spot mutations following cfDNA isolation from the blood plasma and tissues obtained from 30 colorectal cancer patients. The correlation of mutations between the primary tissues and plasma from the patients was high using this platform with whole genome sequencing compared to the spin-column method. This platform can also be combined with various detection approaches (biooptical sensor, Sanger sequencing, and polymerase chain reaction (PCR)) for rapid, simple, low-cost, and sensitive circulating tumor DNA detection in blood plasma. The efficiency and versatility of this platform in isolating cfNAs from liquid biopsies has applications in cancer treatment and precision medicine.

AB - Cell-free nucleic acids (cfNAs) are emerging diagnostic biomarkers for monitoring the treatment and recurrence of cancers. In particular, the biological role and clinical usefulness of cfNAs obtained from the plasma of patients with various cancers are popular and still intensely explored, yet most studies are limited by technical problems during cfNA isolation. A dimethyl dithiobispropionimidate (DTBP)-based microchannel platform that enables spontaneous cfNA capture in 15 min with minimal cellular background and no requirements for use of bulky instruments is reported first. This platform identified KRAS and BRAF hot-spot mutations following cfDNA isolation from the blood plasma and tissues obtained from 30 colorectal cancer patients. The correlation of mutations between the primary tissues and plasma from the patients was high using this platform with whole genome sequencing compared to the spin-column method. This platform can also be combined with various detection approaches (biooptical sensor, Sanger sequencing, and polymerase chain reaction (PCR)) for rapid, simple, low-cost, and sensitive circulating tumor DNA detection in blood plasma. The efficiency and versatility of this platform in isolating cfNAs from liquid biopsies has applications in cancer treatment and precision medicine.

UR - http://www.scopus.com/inward/record.url?scp=85051091208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051091208&partnerID=8YFLogxK

U2 - 10.1002/advs.201800614

DO - 10.1002/advs.201800614

M3 - Article

AN - SCOPUS:85051091208

VL - 5

JO - Advanced Science

JF - Advanced Science

SN - 2198-3844

IS - 10

M1 - 1800614

ER -

Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this